Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
7 Cards in this Set
- Front
- Back
|
Glatiramer acetate |
Copaxone Mechanism: solubilized myelin basic protein antigens (4); injectable and reduces relapse frequency by ~30% AE: injection site reactoins |
|
|
Beta interferons |
Avonex, Rebif Mechanism: alters cytokine activity; injectable and reduces relapse frequency by ~30% AE: flu-like symptoms, can develop antibodies to this |
|
|
Fingolimod |
Gilenya Mechanism: sphingosine 1 receptor modulator resulting in decreased lymphocyte egress from lymph nodes; oral and reduces relapse frequency by 30-50% AE: cardiac conduction abnormalities, lymphopenia (asymptomatic), LFT elevation; likely increases risk of PML if used before treating with natalizumab |
|
|
Teriflunomide |
Aubagio Mechanism: non-specific immunosuppressant; oral and reduces relapse rate by ~30% AE: LFT elevation, hair loss, birth defects, increased infection risk |
|
|
Dimethyl fumarate |
Tecfidera Mechanism of action: Nicotinic acid receptor antagonist; oral (BID) and reduces relapse rate by 30-50% AE: red discoloration of body/flushing (idiosyncratic), significant GI distress (can try slower titration), neutropenia (symptomatic) |
|
|
Natalizumab |
Tysabri Mechanism of action: monoclonal antibody directed against 4-alpha integrin receptor on lymphocytes decreases lymphocyte chemotaxis into CNS (decreased binding to VCAM-1); monthly infusion, reduces risk of relapse by >70% AE: anaphylaxis - stop infusion and cannot retry; PML, particularly if JCV positive or taking for > 2 years (~1 in 1000 chance overall) |
|
|
Mitoxantrone |
Mechanism: anti-neoplastic agent; approved for secondary progressive MS AE: cardiac toxicity, increased risk of leukemia |
